:

Ashley Horne1, Ken Harada2, Katherine D Brown3

  • 1Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Radiation Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.

概括

针对肺癌的个性化放射治疗正在推进,但需要更好的生物标志物,以确保所有患者获得最佳的个性化治疗,以改善结果.